CClinicalTrials.gg
Status unknownNCT03817073Updated Jan 25, 2019

Assessing Fatiguability of Tongue Muscles in MS

An interventional study of Iowa Oral Performance Instrument (IOPI) in Muscle Weakness, Fatigue and Multiple Sclerosis, sponsored by Thomas More Kempen. Status unknown at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-01-25.

Sponsored by Thomas More Kempen · Not applicable, Interventional, and Screening

The sponsor has not verified this record recently (last verified Jan 2019), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Multiple Sclerosis (MS) patients with subjective dysphagia will be tested for tongue strength fatigue using a strictly defined fatigue paradigm. A maximum of 40 sets will be performed, each set consisting of 5 repetitions of 80% of maximum isometric pressure (MIP) at the anterior tongue, followed by a MIP at the anterior tongue. Cut-off criteria are a MIP \<50% of the baseline MIP, pronounced subjective discomfort and/or exceeding the allocated test time of 30 minutes.

Read the detailed description

Eligibility is Mini-Mental State Exam-score (MMSE) > 23, a Eating Assessment Tool-score (EAT-10) > 3, or a Functional Oral Intake Scale-score (FOIS) \< 7, or failing the Yale Swallow Protocol.

02

Conditions studied

  • Muscle Weakness
  • Fatigue
  • Multiple Sclerosis
  • Deglutition Disorders
  • Exertion; Excess
03

In context

Muscle Weakness

601 studies on the registry are indexed under Muscle Weakness; 99 are open to participants now.

This study's planned enrollment of 60 is above the median of 46 across 444 interventional studies indexed under Muscle Weakness.

Browse Muscle Weakness studies →

Lead sponsor

Thomas More Kempen is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • proven MS
  • subjective dysphagia

Exclusion criteria

Exclusion Criteria:

  • MMSE \< 23
  • major head and neck surgery
  • history of cancer
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Iowa Oral Performance Instrument (IOPI)

    All MS patients will be included in this arm to compare with a historical control arm. Iowa Oral Performance Instrument (IOPI).

    Device: Iowa Oral Performance Instrument (IOPI)

Interventions

  • DeviceIowa Oral Performance Instrument (IOPI)

    Using biofeedback to attain repetitions of 80% of baseline MIP.

06

What researchers measure

Primary outcomes

  1. Number of successful repetitions

    The number of repetitions where the target force was developed.

    Time frame: 30 minutes

  2. Evolution of MIP during subsequent repetitions

    The change in MIP after each 5 repetitions.

    Time frame: 30 minutes

Secondary outcomes

  1. Baseline MIP as predictor for number of repetitions

    Does baseline MIP predict the number of successful repetitions.

    Time frame: 30 minutes

07

Study locations

1 site
  • Thomas More University College of Applied Sciences
    Antwerp, Antwerpen 2018, Belgium
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 25, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03817073
Lead sponsor
Thomas More Kempen
Collaborators
Revalidatie & MS Centrum Overpelt
Responsible party
Jan Vanderwegen (Principal Investigator, Clinical Professor, Thomas More Kempen) — Principal investigator
First posted
Jan 25, 2019
Start date
Mar 1, 2019 (estimated)
Primary completion
Jul 1, 2021 (estimated)
Completion
Jul 1, 2021 (estimated)
Last update
Jan 25, 2019

Study contacts

Jan Vanderwegen, MD
Contact
jan.vanderwegen@thomasmore.be
03 241 08 29
Jan Vanderwegen
principal investigator · Thomas More University College

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion